Printable version IAVI and biotechnology company, Lentigen Corporation, announced a collaboration to design a preventive AIDS vaccine based on Lentigen's technology. The candidate AIDS vaccine will be devised to safely mimic biological aspects of HIV infection and will be tested first in pre-clinical studies as part of an initial 18-month agreement. The use of Lentigen's technology could allow researchers to come remarkably close to the live-attenuated strategy of HIV vaccine development. The announcement is below.
| Attachment | Size |
|---|---|
| 4-22-10 lentigen Press Release FINAL.pdf | 114.01 KB |
